e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 521

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani; Ali Abbas; Fatima Abbas; Mustafa Abbas; Sadia Abbasi; Hakam Abbass; Alfie Abbott; Nabeel Abdallah · 2021 · The Lancet

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care al

Abstract by Obbina Abani; Ali Abbas; Fatima Abbas; Mustafa Abbas; Sadia Abbasi; Hakam Abbass; Alfie Abbott; Nabeel Abdallah, The Lancet (2021) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1016/s0140-6736(21)00897-7